Hangzhou Repugene Technology Co., Ltd. is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.
Accurate medical treatment, testing first--Rip gene was invited to appear at the 2018 annual meeting of the Hebei Provincial Ant
Rip Gene was invited to participate in the 2018 Annual Meeting of the Lung Cancer Professional Committee of the Hebei Anti-Cancer Association, the 2018 Annual Meeting of the Thoracic Surgeon Branch of the Hebei Provincial Doctors Association and the Inaugural Meeting of the Lung Cancer Professional Committee of the Hebei Cancer Prevention and Control Federation, which attracted great attention from the industry! The conference focused on basic research on lung cancer and esophageal cancer, and attracted many clinical caffes to enter the academic feast, and conducted in-depth exchanges and discussions on the latest clinical diagnosis and treatment standards. The conference was held in Shijiazhuang, Hebei Province!
The opening ceremony was delivered by Professor Yu Cuizhi, Vice President of the Fourth Hospital of Hebei Medical University, and Professor Liu Junfeng, Director of the Department of Thoracic Surgery, the Fourth Hospital of Hebei Medical University.
Professor Jade Cuizhi, Professor Liu Junfeng
With the advent of the era of precision medicine, NGS testing has become an indispensable part of clinical cancer diagnosis and treatment. As a leading precision medical enterprise, Ripple has been providing personalized and accurate medical services for every patient. Constantly moving forward, it is recognized by the industry. At the conference, Dr. Wang Tao, Director of Ripple's Gene Digital Health, was invited to participate in the special report on the guiding significance of NGS testing in the clinic. The report was rich and novel and benefited a lot.
Dr. Wang Tao
Dr. Wang Tao introduced that "precise treatment, detection first", molecular detection technology such as NGS plays an important role in tumor targeted therapy, immunotherapy and neoadjuvant therapy. In targeted therapy, the drug response is not only related to the mutation status of the target site, but also to other co-mutation sites, and patients develop resistance and progression with the treatment process, which requires high-throughput sequencing of NGS. Technology to fully understand molecular information and its mechanisms of resistance to guide the next treatment. In current clinical tests, liquid biopsy (ctDNA) is increasingly used, for example, as a supplement to tissue testing, early screening of tumors, diagnosis and classification, dynamic monitoring of treatment, and prediction of recurrence risk after surgery.
In immunotherapy, Dr. Wang introduced the detection of immunological checkpoint inhibitor markers such as PD-L1 and TMB. The detection of PD-L1 is related to instrument platform, antibody and interpretation of results. In clinical applications, attention should be paid to the consistency of different platforms. As another important marker, TMB has been written into the new NCCN guidelines, and NGS is an indispensable tool for detecting this indicator. The level of TMB is related to the mutation of the driving mutation gene and the mismatch repair gene. The efficacy of TMB-guided immunotherapy drugs is also related to some gene mutations. In immunotherapy, combination therapy is an important clinical Application ideas. In addition, NGS also plays an important role in clinical applications such as pharmacogenomics, hereditary health screening, single cell sequencing, and TCR sequencing.
The conference was hosted by the Hebei Provincial Anti-Cancer Association Lung Cancer Professional Committee, the Hebei Provincial Medical Association Thoracic Surgery Branch, and the Hebei Provincial Cancer Prevention Association, and the Fourth Hospital of Hebei Medical University.